Your browser doesn't support javascript.
loading
Tumor Intrinsic Efficacy by SHP2 and RTK Inhibitors in KRAS-Mutant Cancers.
Hao, Huai-Xiang; Wang, Hongyun; Liu, Chen; Kovats, Steven; Velazquez, Roberto; Lu, Hengyu; Pant, Bhavesh; Shirley, Matthew; Meyer, Matthew J; Pu, Minying; Lim, Joanne; Fleming, Michael; Alexander, LeighAnn; Farsidjani, Ali; LaMarche, Matthew J; Moody, Susan; Silver, Serena J; Caponigro, Giordano; Stuart, Darrin D; Abrams, Tinya J; Hammerman, Peter S; Williams, Juliet; Engelman, Jeffrey A; Goldoni, Silvia; Mohseni, Morvarid.
Afiliación
  • Hao HX; Disease Area Oncology, Novartis Institute of Biomedical Research, Cambridge, Massachusetts.
  • Wang H; Disease Area Oncology, Novartis Institute of Biomedical Research, Cambridge, Massachusetts.
  • Liu C; Disease Area Oncology, Novartis Institute of Biomedical Research, Cambridge, Massachusetts.
  • Kovats S; Disease Area Oncology, Novartis Institute of Biomedical Research, Cambridge, Massachusetts.
  • Velazquez R; Disease Area Oncology, Novartis Institute of Biomedical Research, Cambridge, Massachusetts.
  • Lu H; Disease Area Oncology, Novartis Institute of Biomedical Research, Cambridge, Massachusetts.
  • Pant B; Disease Area Oncology, Novartis Institute of Biomedical Research, Cambridge, Massachusetts.
  • Shirley M; Disease Area Oncology, Novartis Institute of Biomedical Research, Cambridge, Massachusetts.
  • Meyer MJ; Disease Area Oncology, Novartis Institute of Biomedical Research, Cambridge, Massachusetts.
  • Pu M; Disease Area Oncology, Novartis Institute of Biomedical Research, Cambridge, Massachusetts.
  • Lim J; Exploratory Immuno-Oncology, Novartis Institute of Biomedical Research, Cambridge, Massachusetts.
  • Fleming M; Exploratory Immuno-Oncology, Novartis Institute of Biomedical Research, Cambridge, Massachusetts.
  • Alexander L; Disease Area Oncology, Novartis Institute of Biomedical Research, Cambridge, Massachusetts.
  • Farsidjani A; Disease Area Oncology, Novartis Institute of Biomedical Research, Cambridge, Massachusetts.
  • LaMarche MJ; Global Discovery Chemistry, Novartis Institute of Biomedical Research, Cambridge, Massachusetts.
  • Moody S; Disease Area Oncology, Novartis Institute of Biomedical Research, Cambridge, Massachusetts.
  • Silver SJ; Disease Area Oncology, Novartis Institute of Biomedical Research, Cambridge, Massachusetts.
  • Caponigro G; Disease Area Oncology, Novartis Institute of Biomedical Research, Cambridge, Massachusetts.
  • Stuart DD; Disease Area Oncology, Novartis Institute of Biomedical Research, Cambridge, Massachusetts.
  • Abrams TJ; Disease Area Oncology, Novartis Institute of Biomedical Research, Cambridge, Massachusetts.
  • Hammerman PS; Disease Area Oncology, Novartis Institute of Biomedical Research, Cambridge, Massachusetts.
  • Williams J; Disease Area Oncology, Novartis Institute of Biomedical Research, Cambridge, Massachusetts.
  • Engelman JA; Disease Area Oncology, Novartis Institute of Biomedical Research, Cambridge, Massachusetts.
  • Goldoni S; Disease Area Oncology, Novartis Institute of Biomedical Research, Cambridge, Massachusetts.
  • Mohseni M; Disease Area Oncology, Novartis Institute of Biomedical Research, Cambridge, Massachusetts. morvarid.mohseni@novartis.com.
Mol Cancer Ther ; 18(12): 2368-2380, 2019 12.
Article en En | MEDLINE | ID: mdl-31439712
KRAS, an oncogene mutated in nearly one third of human cancers, remains a pharmacologic challenge for direct inhibition except for recent advances in selective inhibitors targeting the G12C variant. Here, we report that selective inhibition of the protein tyrosine phosphatase, SHP2, can impair the proliferation of KRAS-mutant cancer cells in vitro and in vivo using cell line xenografts and primary human tumors. In vitro, sensitivity of KRAS-mutant cells toward the allosteric SHP2 inhibitor, SHP099, is not apparent when cells are grown on plastic in 2D monolayer, but is revealed when cells are grown as 3D multicellular spheroids. This antitumor activity is also observed in vivo in mouse models. Interrogation of the MAPK pathway in SHP099-treated KRAS-mutant cancer models demonstrated similar modulation of p-ERK and DUSP6 transcripts in 2D, 3D, and in vivo, suggesting a MAPK pathway-dependent mechanism and possible non-MAPK pathway-dependent mechanisms in tumor cells or tumor microenvironment for the in vivo efficacy. For the KRASG12C MIAPaCa-2 model, we demonstrate that the efficacy is cancer cell intrinsic as there is minimal antiangiogenic activity by SHP099, and the effects of SHP099 is recapitulated by genetic depletion of SHP2 in cancer cells. Furthermore, we demonstrate that SHP099 efficacy in KRAS-mutant models can be recapitulated with RTK inhibitors, suggesting RTK activity is responsible for the SHP2 activation. Taken together, these data reveal that many KRAS-mutant cancers depend on upstream signaling from RTK and SHP2, and provide a new therapeutic framework for treating KRAS-mutant cancers with SHP2 inhibitors.
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Taquicininas / Proteínas Proto-Oncogénicas p21(ras) / Proteína Tirosina Fosfatasa no Receptora Tipo 11 / Neoplasias Límite: Animals / Female / Humans Idioma: En Revista: Mol Cancer Ther Asunto de la revista: ANTINEOPLASICOS Año: 2019 Tipo del documento: Article Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Taquicininas / Proteínas Proto-Oncogénicas p21(ras) / Proteína Tirosina Fosfatasa no Receptora Tipo 11 / Neoplasias Límite: Animals / Female / Humans Idioma: En Revista: Mol Cancer Ther Asunto de la revista: ANTINEOPLASICOS Año: 2019 Tipo del documento: Article Pais de publicación: Estados Unidos